cyrilzakka/clinical-trials huggingface dataset:
Empowerment Program for Cancer Survivors

This study aims to decrease cancer survivors' intrusive ruminative thoughts and cancer-related fatigue and increase their purposive ruminative thoughts and psychological resilience. In this context, an online (Zoom) 10-session empowerment program based on the literature will be implemented for cancer survivors.

From the time they were diagnosed with cancer, individuals struggle with ruminative thoughts about why they have this disease, whether they will get better during the treatment process, whether the disease will recur in the future, and cognitive, physical, and emotional fatigue, the cause of which cannot be fully explained. All these processes continue to negatively affect the lives of cancer survivors during the remission period. Studies show that when cancer survivors manage this stressful process well and learn effective coping methods, they can come out of it by developing their psychological resilience. Therefore, this study aimed to determine the effect of an empowerment program to be applied to cancer survivors' ruminative thoughts, cancer-related fatigue, and psychological resilience.

The hypotheses of this research are:

H 1-1: There is a difference between ruminative thinking scores at the end of the empowerment program applied to individuals with cancer in remission and in the follow-up measurement compared to the pre-program and control groups.

H 1-2: There is a difference between cancer-related fatigue scores at the end of the empowerment program applied to individuals with cancer in remission and in the follow-up measurement compared to the pre-program and control groups.

H 1-3: There is a difference between psychological resilience scores at the end of the empowerment program applied to individuals with cancer in remission and in the follow-up measurement compared to the pre-program and control groups.

Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the research,
* Being between the ages of 18-65,
* To have knowledge of reading and writing in Turkish,
* Being in remission
* To have technical equipment (camera, microphone, computer) and usage knowledge to participate in the online group session

Exclusion Criteria:

- To have received psychological support in the last year
Retrospective Analysis of TEM and TEM-ESD for the Treatment of Rectal Adenomas and Early Rectal Cancer

We retrospectively analysed all TEM and TEM-ESD procedures that took place in Surgical Clinic of the Municipal Hospital of Karlsruhe and the Surgery Department of the University Hospital of Mannheim from 2007 to 2021. We evaluated the periopüerative and long-term outcomes of both procedures for adenomas, adenocarcinomas and other tumours seperately and we compared the results between the two techniques.


Eligibility Criteria:
Inclusion Criteria:

* Patients who underwent TEM or TEM-ESD

Exclusion Criteria:

-
Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring

Primary:

Evaluate the degree of correction attainable with Poly-L-Lactic Acid(Sculptra) for the correction of hill and valley acne scarring

Secondary:

Document types and incidence of device adverse events with Poly-L-Lactic Acid(Sculptra) therapy.


Eligibility Criteria:
Inclusion Criteria:

* Outpatient seeking therapy for correction of hill and valley acne scarring.
* Ability and willingness to understand and comply with requirements of the trial

Exclusion Criteria:

* The subject has active acne or chronic skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster
* History of presence of keloid formation or hypertrophic scars
* History of procedures that precipitate an active dermal inflammatory or hyperplastic response (i.e., epilation or radiofrequency laser and chemical peeling procedures) within one month of study entry
* History of use of facial tissue augmenting therapy or aesthetic facial surgical therapy within six months prior to study entry
* Concomitant anticoagulant therapy, antiplatelet therapy or has any bleeding disorders
* History of unanticipated adverse reactions when treated with hyaluronic acid based products
* Any condition which in the opinion of the investigator makes the patient unable to complete the study per protocol (e.g., patients not likely to avoid other facial cosmetic treatments; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments)
* History of or current cancerous or pre-cancerous lesions in the area to be treated
* Use of any investigational drugs or any other medical devices within 30 days of enrolment
* Use of any prohibited medication within a proscribed time period before entry
* Pregnancy
* Recent use of Accutane (patient should not be on Accutane for the last 6 months)
* History of allergic/anaphylactic reactions, including hypersensitivity to local anaesthetics (lidocaine)
* Recent history of trauma in the face (less that 1 year)
* Previous of Dermalive or Dermadeep

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Neuropsychiatric Effects of Deep Brain Stimulation in Patients With Parkinson's Disease

Stimulation of the subthalamic nucleus will have effects on various aspects of neuropsychiatric function.


Eligibility Criteria:
Inclusion Criteria:

* Participants diagnosed with idiopathic Parkinson's disease that meet criteria for treatment of their disease with STN-DBS. Participants will be selected for this study without regard for age (provided they are older than 18), gender or ethnic background.
* Participants must have undergone subthalamic nucleus DBS surgery and be receiving treatment at the Scripps Clinic in La Jolla, CA

Exclusion Criteria:

* Patients under 18 years old.
* Patients with mini-mental status scores below 26/30.
* Patients with known psychiatric disease.
* Patients who are too infirm, demented or dysarthric to clearly understand the consenting process, task instructions, or to communicate verbally regarding participation or non-participation.
Study of Pathways Curriculum for Use With WPD

Study to assess the efficacy of a modified Pathways curriculum in treating depressive symptoms in women with physical disabilities.


Eligibility Criteria:
Inclusion Criteria:

* Women with physical disability requiring accommodation for major mobility limitations
* CES-D score of 16 or higher -

Exclusion Criteria:

* Active suicidality
* Diagnosis of Schizophrenia, Schizoaffective D/O, Psychosis NOS
* Currently receiving other psychotherapy -
Optimization Principles in Hemiparetic Gait

This project seeks to identify the how walking impairments in stroke survivors contribute to mobility deficits through the use of behavioral observations and computational models. The chosen approach integrates biomechanical analyses, physiological assessments and machine learning algorithms to explain how asymmetries during walking influence balance and the effort required to walk. Ultimately, the results of this work may lead to more personalized rehabilitation strategies to improve walking capacity and efficiency, and ultimately reduce fall risk in stroke survivors.


Eligibility Criteria:
Inclusion Criteria for Control Participants:

* No musculoskeletal injury or conditions that limit walking ability
* No history of neurological disorders or severe head trauma
* Absence of cognitive impairment as demonstrated by a Mini-Mental score greater than 24

Inclusion Criteria for Post-Stroke Participants

* Presence of unilateral brain lesion from a single stroke
* Weakness confined to one side
* Ability to walk on a treadmill for five minutes continuously without a cane or walker
* Absence of cognitive impairment as demonstrated by a Mini-Mental score greater than 24
Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia

In this study, we tried to demonstrate clinical benefit of additive danazol to romiplostim therapy in patients with eltrombopag-resistant immune thrombocytopenia

The patients with eltrombopag-resistant immune thrombocytopenia are treated with romiplostim and danazol. The efficacy and toxicity of treatment will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* aged over 18 years
* diagnosed with immune thrombocytopenia (bone marrow examination is not necessary)
* failed to achieve platelet count over 50X10\^9/L with eltrombopag
* ECOG performance status 0,1,2
* available to obtain informed consent

Exclusion Criteria:

* Hepatitis B or C carriers
* HIV positive patients
* diagnosed with systemic lupus erythematosus or other autoimmune disorders
* unable to intake orally or absorb through gastrointestinal tract
* pregnant or breast-feeding
* diagnosed with uncontrolled seizure or other neuropsychiatric disorders
* diagnosed with clinically significant cardiovascular events within 6 months or dyspnea on exertion evaluated to New York Heart Association Functional Classification III or IV
* diagnosed with clinically significant cerebrovascular disorders
* previously diagnosed or treated with thromboembolism
* current treating malignant diseases
* currently accompanied by uncontrolled infection or active bleeding
* with blood test results as follows; total bilirubin \> 2xUNL(upper normal limit), AST/ALT \> 1.5xUNL, creatinine \> 1.5xUNL, glomerular filtration rate \< 30ml/min/1.73m\^2
* registered to other clinical trials for treatment of immune thrombocytopenia
* judged to be inappropriate for clinical trial by doctor in charge
CNS Qualitative Interview

Explore factors involved in decision making for patients with new or recurrent CNS tumors and their families surrounding treatment planning and clinical trial enrollment.

Explore factors involved in decision making for patients with new or recurrent CNS tumors and their families surrounding treatment planning and clinical trial enrollment. The team will conduct qualitative interviews with a diverse group of patients and families considering treatment for new and recurrent CNS tumors to determine challenges surrounding treatment and study enrollment that may be modifiable through community, hospital, and University of Colorado Cancer Center resources. The team will then assess the impact of these resources on decision making through follow-up interviews.

Eligibility Criteria:
Inclusion Criteria:

1. Be the parent or caregiver of a child or young adult receiving treatment at CHCO

   a. Child must meet one criterion below: i. Newly diagnosed with a CNS tumor ii. Relapse of a CNS tumor requiring further therapy. Therapy may be standard of care of dictated by an open clinical trial
2. Patient 18 years of age or older a. Must meet one of the criteria below: i. Newly diagnosed with a CNS tumor ii. Relapse of a CNS tumor requiring further therapy. Therapy may be standard of care of dictated by an open clinical trial

Exclusion Criteria:

* Does not meet inclusion criteria
Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19

Fatigue is common and disabling in patients with post-COVID syndrome. There is no treatment available at this moment, and fatigue has important consequences. The main aim of this study is to evaluate the changes in the severity of fatigue using non-invasive neuromodulation in patients with post-COVID condition. This is a randomized, parallel, double-blind, placebo-controlled clinical trial using transcranial direct current stimulation. Secondary aims include changes in cognition, depression, and quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of COVID-19 with PCR-confirmation.
* Fatigue linked to COVID-19
* No diagnosis of neurological, psychiatric or medical disorder with potential impact on fatigue.

Exclusion Criteria:

* Stroke before COVID-19
* History of traumatic brain lesion or central nervous system infection previous to COVID-19
* Radiotherapy or chemotherapy for cancer
* Severe sensorial deficits
* Drugs or uncontrolled medical disorder with potential impact on fatigue.
* History of abuse of alcohol or other toxics.
* Any contraindication for tDCS (metallic implants, brain devices, pacemakers, head injuries).
Protocol to Assess the Severity of Acute Kidney Injury

The principal objective is to safely determine if we can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled, we will draw blood and urine for relevant biomarkers. Our goal is to validate if any of these biomarkers can predict the course of AKI (recovery v. RRT v. death)

AKI is a very common disease in the intensive care unit. However, despite advances in supportive care, patients with AKI carry a high mortality rate (50% to 70%). The established AKI affects nearly 5 percent of hospitalized persons and as many as 15 percent of critically ill patients. Currently, there are no FDA approved therapeutic agents for the treatment of AKI.

Retrospective studies suggest that the early initiation of renal replacement therapy (RRT) improves outcome. Many clinicians tend to take a "wait and see" approach because they do not want to dialyze a patient who is destined to recover renal function without the need for RRT. Therefore, it is vitally important to know early in the course which patients with AKI are likely to progress to RRT.

Eligibility Criteria:
Inclusion Criteria:

* 18 years and older
* Increase in serum creatinine of 0.3 mg/dl within 48 hours or an increase of greater or equal to 150 to 200% from baseline or sustained oliguria(mean urine output of \<0.5 cc/kg/hr for 6 hours within 48 hours)
* Written informed consent
* Patients who already have a indwelling bladder catheter

Exclusion Criteria:

* Voluntary refusal or missing written consent of the patient or the designated legal representative
* Patients with advanced Chronic Kidney Disease - as defined by a baseline GFR of \< 30 ml/min as calculated by the MDRD equation
* Patients with renal transplantation
* Pregnancy
* Patients with an allergy or sensitivity to loop diuretics
* Patients with a clinical syndrome consistent with pre-renal AKI

  * Defined by fractional excretion of Na of \< 1% AND no evidence of the urinary casts, or
  * Patients that are under-resuscitated as deemed by treating clinical team or
  * Patients who are actively bleeding
* Patients with a clinical syndrome of post-renal AKI

  * Any radiological study that shows hydro-ureter, or
  * Clinical scenario wherein the obstruction is considered a likely possibility of the cause of AKI
Effectiveness of Smart-Video Based Game Therapy and Otago-Based Structured Exercises in Women With Osteoporosis

In this project, researchers evaluated the effects and differences of smart-video based game therapy and Otago-based structured exercises in women with osteoporosis; aimed to evaluate their applicability in women with osteoporosis.

Osteoporosis is a musculoskeletal disease characterized by decreased bone mass and deterioration of the microstructure of the bone. The aim of the study is to use smart-based video-based play therapy and Otago-based structured exercises in women with osteoporosis; To evaluate the effect on bone quality, lower extremity muscle strength, balance, fear of falling, kinesiophobia and quality of life.

Working Groups Group 1: Smart Based Video Based Game Therapy Group Group 2: Otago Based Structured Exercise Group Group 3: Control Group Participants who agree to participate in the study are first evaluated with the Mental State Assessment - Standardized Mini Mental Test and Game Therapy group with the Simulator Illness Questionnaire and System Usability Scale, and if they meet the participation criteria, our study involves face-to-face interviews and blood and urine samples are routinely performed by the doctor on all patients at their first visit. Bone quality will be evaluated using bone turnover markers. Static balance with Romberg Test, dynamic balance with Four Square Step Test, functionality with Timed Up and Go Test, fear of falling with International Fall Activity Scale, kinesiophobia with Tampa Kinesiophobia Scale, muscle strength with Myometer, quality life with European Osteoporosis Association Quality of Life Questionnaire-41 will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Women in the climacteric period with osteoporosis between the ages of 45-65
* Those with DEXA T score \< -2.5 SD,
* Those who have independent ambulation,
* Those who have no history of falling in the last year
* Those with a mini mental test score of 24 and above

Exclusion Criteria:

* Those who have participated in any exercise program in the last 3 months,
* Those who need support in ambulation,
* Those with a history of pathological fracture due to significant post-traumatic or malignancy,
* Those who have any systemic disease that may hinder the practices,
* Those with vestibular dysfunction,
* For participants in the smart video-based game therapy group, those who are not suitable to use the system according to the System Usability Scale and Simulator Illness Questionnaire
VR for Joint Attention Support in ASD

The overall objective of this study is to determine the effectiveness of the Floreo VR Joint Attention Module in improving social communication skills in children with ASD. An additional objective is ongoing investigation of the tolerability of the product and the extent of potential adverse effects of Floreo VR, if any.

The study will be a Phase II randomized controlled trial in which the Floreo VR Joint Attention Module is the intervention being evaluated. Floreo is a mobile application that offers a supervised virtual reality experience for individuals with ASD. The application provides a 3D immersive scene for Google Cardboard-compatible smartphones and a WiFi paired supervisory overview that can run on smartphones or tablets.

The therapeutic content will consist of a Learning Module focused on Joint Attention. This Joint Attention Learning Module will include separate Learning Cards (LCs) that address specific subskills necessary to develop appropriate joint attention. Each Learning Card will consist of a virtual reality environment in a safari-themed setting, complete with animals designed to draw the learner's attention when necessary.

The product will be implemented at The Children's SPOT by a therapist working with a client during the course of a therapy session.

The intervention arm participant would engage in one or two VR episodes during a scheduled session. Each episode would last no more than 5 minutes. If two episodes are done in a day, there is a mandatory break of at least 3 minutes in between them. The sessions would occur two days per week, with at least two days in between sessions to allow the eyes time to rest.

There are 15 total VR sessions in the protocol, and completion of all study sessions would take 8 weeks.

The control condition is treatment as usual, that is, regularly scheduled therapy.

Eligibility Criteria:
Inclusion Criteria:

* Documented ASD diagnosis, between 7 and 17 years of age

Exclusion Criteria:

* History of seizures, migraines, vertigo, psychosis
Sun Protection Factor Assay (SPF Assay 203/2016)

To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility Criteria:
Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female.
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF (Subject History Form).
* Signed and dated Informed Consent Form.
* Signed and dated HIPAA (Health Insurance Portability and Accountability Act) form.
* An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose).

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma, diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.
Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation

The incidence of end stage renal disease (ESRD) is rapidly increasing, now affecting an estimated 7.4 million people worldwide. Numerous parameters such as demographic, clinical and functional factors drive the deterioration of the kidney, ultimately leading to ESRD. Although some ESRD prediction models have been derived in the past years, none of these models are dynamic: they do not integrate the repeated measurements recorded throughout individuals' follow-up.

As highlighted in several studies, kidney function repeated measurements (i.e., trajectories) are highly associated with graft survival after kidney transplantation. The investigators made the hypothesis that these trajectories may bring relevant information in the context of graft survival risk prediction model. Hence, combining these trajectories with standard graft survival risk factors may enhance prediction performance. This could permit to derive a robust tool that could be updated over time by continuously capturing patient' personal evolution.

850 million individuals suffer from chronic kidney disease (CKD), while diabetes, cancer, and HIV/AIDS affect 422, 42, and 37 million individuals, respectively. End stage renal disease (ESRD) hence places a heavy burden on health systems worldwide. Linked to that, the kidney-disease-associated mortality rate worldwide has risen over the past decade, now causing the death of 5 to 10 million individuals every year.

In kidney transplantation, numerous parameters such as demographic, clinical and functional factors drive the deterioration of the kidney, sometimes leading to graft failure. Current approaches for investigating the relationship between these factors and graft failure have been limited by standard statistical approaches and by registries with an overall lack on granular data, including infrequent kidney function measurements for a single patient and convenience clinical samples. Identifying the determinants of graft failure with a dynamic approach may bring an original perspective to the traditional graft survival risk prediction model that are impeded by their reliance on low-granularity datasets, cross-sectional parameters, and limited follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Kidney recipients transplanted after 2004
* Kidney recipients over 18 years of age
* Kidney recipients with at least two estimated glomerular filtration rate and proteinuria measurements after transplantation

Exclusion Criteria:

* Combined transplantation